DocMorris AGXSWX:DOCM -0.34%66 Debt-to-Equity is 0.65 as of Jun. 2025, which is 24% below its 10-year median of 0.86. GuruFocus rates XSWX:DOCM with a GF Score™ of 66/100 and a GF Value™ of CHF10.54 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 557 Healthcare Providers & Services companies, DocMorris AG ranks worse than 61.04% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for DocMorris AG's Debt-to-Equity or its related term are showing as below:
XSWX:DOCM'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.86 Max: 1.51
Current: 0.65
During the past 13 years, the highest Debt-to-Equity Ratio of DocMorris AG was 1.51. The lowest was 0.01. And the median was 0.86.
XSWX:DOCM's Debt-to-Equity is ranked worse than 61.04% of 557
companies
in the Healthcare Providers & Services industry
Industry Median: 0.4
vs XSWX:DOCM: 0.65
DocMorris AG (XSWX:DOCM) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
DocMorris AG Debt-to-Equity Related Terms
DocMorris AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for DocMorris AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, DocMorris AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DocMorris AG Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DocMorris AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where DocMorris AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DocMorris AG (XSWX:DOCM) has a Debt-to-Equity of 0.65 as of Jun. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on DocMorris AG and its competitors. This is 24% below median its historical median of 0.86. Over the past decade, DocMorris AG's Debt-to-Equity has ranged from 0.01 to 1.51. According to the industry distribution chart, DocMorris AG ranks #340 out of 557 companies in the Healthcare Providers & Services industry, placing it in the top 61%.
Is DocMorris AG's Debt-to-Equity too high?
DocMorris AG's current Debt-to-Equity of 0.65 is 24% below median its 10-year median of 0.86. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 1.51. The Healthcare Providers & Services industry median Debt-to-Equity is 0.40. DocMorris AG's value of 0.65 is 62.5% above this industry median. Based on the distribution chart, DocMorris AG ranks #340 out of 557 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, DocMorris AG has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DocMorris AG's Debt-to-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DocMorris AG ranks #340 out of 557 companies for Debt-to-Equity. This places DocMorris AG in the lower half of its industry. The industry median Debt-to-Equity is 0.40. DocMorris AG's value of 0.65 is 62.5% above this benchmark. Historically, DocMorris AG's own Debt-to-Equity has ranged from 0.01 to 1.51 over the past decade. While the company's 10-year median is 0.86 vs. the industry median of 0.40, DocMorris AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.40, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DocMorris AG's current Debt-to-Equity of 0.65 is 62.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on DocMorris AG and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DocMorris AG's current Debt-to-Equity is 0.65, which is 24% below median its own 10-year median of 0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocMorris AG stock overvalued right now?
Based on GuruFocus' analysis, DocMorris AG (XSWX:DOCM) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF10.54, compared to a current price of CHF8.76 — trading 16.9% below its estimated fair value. The current Debt-to-Equity is 0.65, which is 24% below median its 10-year median of 0.86 and 62.5% above the Healthcare Providers & Services industry median of 0.40. DocMorris AG's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For DocMorris AG (XSWX:DOCM), the current Debt-to-Equity is 0.65 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DocMorris AG (XSWX:DOCM) Overvalued in 2026?
Based on GuruFocus' analysis, DocMorris AG stock appears to be undervalued.
The current stock price of CHF8.76 is trading 16.9% below its estimated GF Value™ of CHF10.54.
GuruFocus considers DocMorris AG to be Modestly Undervalued.
Key valuation signals for XSWX:DOCM:
Debt-to-Equity: 0.65 (24% below median its 10-year median of 0.86)
GF Value™: CHF10.54 vs. price of CHF8.76 (16.9% below fair value)
Industry Position: 62.5% above the Healthcare Providers & Services median (#340 of 557)
No single metric tells the full story. See the XSWX:DOCM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DocMorris AG is engaged in the fields of online pharmacy, marketplace, and professional healthcare with brands in Germany and other European countries. Its brands are DocMorris, PromoFarma by DocMorris, and TeleClinic. The Group's reportable segments are Germany and Europe. The Germany segment comprises the mail-order business in drugs and health products, as well as services for mail-order pharmacies. The Europe segment comprises the marketplace business of PromoFarma and Doctipharma. The majority of revenue is generated from Germany segment.
66GF Score
Get the complete analysis for XSWX:DOCM
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:DOCM has been successfully added to your 
